Logo image of NVCR

NOVOCURE LTD (NVCR) Stock Fundamental Analysis

NASDAQ:NVCR - Nasdaq - JE00BYSS4X48 - Common Stock - Currency: USD

11.32  -0.25 (-2.16%)

After market: 11.54 +0.22 (+1.94%)

Fundamental Rating

2

NVCR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of NVCR have multiple concerns. NVCR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

NVCR had negative earnings in the past year.
NVCR had a negative operating cash flow in the past year.
NVCR had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: NVCR reported negative operating cash flow in multiple years.
NVCR Yearly Net Income VS EBIT VS OCF VS FCFNVCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

NVCR has a Return On Assets (-13.15%) which is in line with its industry peers.
NVCR has a Return On Equity (-45.36%) which is in line with its industry peers.
Industry RankSector Rank
ROA -13.15%
ROE -45.36%
ROIC N/A
ROA(3y)-13.14%
ROA(5y)-8.53%
ROE(3y)-41.63%
ROE(5y)-26.99%
ROIC(3y)N/A
ROIC(5y)N/A
NVCR Yearly ROA, ROE, ROICNVCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

NVCR has a better Gross Margin (77.16%) than 90.37% of its industry peers.
NVCR's Gross Margin has been stable in the last couple of years.
NVCR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 77.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.51%
GM growth 5Y0.68%
NVCR Yearly Profit, Operating, Gross MarginsNVCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

1

2. Health

2.1 Basic Checks

NVCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NVCR has more shares outstanding
The number of shares outstanding for NVCR has been increased compared to 5 years ago.
NVCR has a worse debt/assets ratio than last year.
NVCR Yearly Shares OutstandingNVCR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
NVCR Yearly Total Debt VS Total AssetsNVCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

NVCR has an Altman-Z score of -0.06. This is a bad value and indicates that NVCR is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.06, NVCR is in line with its industry, outperforming 44.38% of the companies in the same industry.
A Debt/Equity ratio of 1.81 is on the high side and indicates that NVCR has dependencies on debt financing.
The Debt to Equity ratio of NVCR (1.81) is worse than 84.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.81
Debt/FCF N/A
Altman-Z -0.06
ROIC/WACCN/A
WACC6.4%
NVCR Yearly LT Debt VS Equity VS FCFNVCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

NVCR has a Current Ratio of 1.47. This is a normal value and indicates that NVCR is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of NVCR (1.47) is worse than 76.47% of its industry peers.
A Quick Ratio of 1.41 indicates that NVCR should not have too much problems paying its short term obligations.
NVCR's Quick ratio of 1.41 is on the low side compared to the rest of the industry. NVCR is outperformed by 62.03% of its industry peers.
Industry RankSector Rank
Current Ratio 1.47
Quick Ratio 1.41
NVCR Yearly Current Assets VS Current LiabilitesNVCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 1.27% over the past year.
The Revenue has grown by 14.59% in the past year. This is quite good.
The Revenue has been growing by 11.49% on average over the past years. This is quite good.
EPS 1Y (TTM)1.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.13%
Revenue 1Y (TTM)14.59%
Revenue growth 3Y4.2%
Revenue growth 5Y11.49%
Sales Q2Q%5.62%

3.2 Future

The Earnings Per Share is expected to grow by 17.18% on average over the next years. This is quite good.
The Revenue is expected to grow by 18.62% on average over the next years. This is quite good.
EPS Next Y-7.24%
EPS Next 2Y-8.1%
EPS Next 3Y2.68%
EPS Next 5Y17.18%
Revenue Next Year5.14%
Revenue Next 2Y6.24%
Revenue Next 3Y9.86%
Revenue Next 5Y18.62%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NVCR Yearly Revenue VS EstimatesNVCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
NVCR Yearly EPS VS EstimatesNVCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NVCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NVCR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NVCR Price Earnings VS Forward Price EarningsNVCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NVCR Per share dataNVCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.1%
EPS Next 3Y2.68%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NVCR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NOVOCURE LTD

NASDAQ:NVCR (8/1/2025, 5:37:33 PM)

After market: 11.54 +0.22 (+1.94%)

11.32

-0.25 (-2.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-24 2025-07-24/bmo
Earnings (Next)N/A N/A
Inst Owners87.38%
Inst Owner Change-0.12%
Ins Owners2.69%
Ins Owner Change2.26%
Market Cap1.27B
Analysts80
Price Target33.08 (192.23%)
Short Float %4.91%
Short Ratio3.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-19.69%
Min EPS beat(2)-73.92%
Max EPS beat(2)34.54%
EPS beat(4)3
Avg EPS beat(4)1.12%
Min EPS beat(4)-73.92%
Max EPS beat(4)34.54%
EPS beat(8)6
Avg EPS beat(8)5.58%
EPS beat(12)7
Avg EPS beat(12)-5.98%
EPS beat(16)8
Avg EPS beat(16)-115.75%
Revenue beat(2)2
Avg Revenue beat(2)1.92%
Min Revenue beat(2)0.18%
Max Revenue beat(2)3.65%
Revenue beat(4)4
Avg Revenue beat(4)4.5%
Min Revenue beat(4)0.18%
Max Revenue beat(4)8.53%
Revenue beat(8)5
Avg Revenue beat(8)2.21%
Revenue beat(12)6
Avg Revenue beat(12)0.92%
Revenue beat(16)7
Avg Revenue beat(16)-0.51%
PT rev (1m)-2.71%
PT rev (3m)-4.62%
EPS NQ rev (1m)1.63%
EPS NQ rev (3m)19.25%
EPS NY rev (1m)0.51%
EPS NY rev (3m)17.34%
Revenue NQ rev (1m)0.22%
Revenue NQ rev (3m)2.73%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)2.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.04
P/FCF N/A
P/OCF N/A
P/B 3.5
P/tB 3.5
EV/EBITDA N/A
EPS(TTM)-1.56
EYN/A
EPS(NY)-1.82
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS5.56
BVpS3.24
TBVpS3.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.15%
ROE -45.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 77.16%
FCFM N/A
ROA(3y)-13.14%
ROA(5y)-8.53%
ROE(3y)-41.63%
ROE(5y)-26.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.51%
GM growth 5Y0.68%
F-Score5
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 1.81
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 354.89%
Cap/Sales 6.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.47
Quick Ratio 1.41
Altman-Z -0.06
F-Score5
WACC6.4%
ROIC/WACCN/A
Cap/Depr(3y)276.52%
Cap/Depr(5y)245.8%
Cap/Sales(3y)5.46%
Cap/Sales(5y)4.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.13%
EPS Next Y-7.24%
EPS Next 2Y-8.1%
EPS Next 3Y2.68%
EPS Next 5Y17.18%
Revenue 1Y (TTM)14.59%
Revenue growth 3Y4.2%
Revenue growth 5Y11.49%
Sales Q2Q%5.62%
Revenue Next Year5.14%
Revenue Next 2Y6.24%
Revenue Next 3Y9.86%
Revenue Next 5Y18.62%
EBIT growth 1Y22.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year55.91%
EBIT Next 3Y24.94%
EBIT Next 5Y42.57%
FCF growth 1Y-1464.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-271.61%
OCF growth 3YN/A
OCF growth 5YN/A